Trial | NCT00664222  Report issue

Title

Spironolactone and Insulin Resistance in Chronic Heart Failure (CHF)
Effects of Spironolactone on Insulin Resistance in Patients With Chronic Heart Failure

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    16
The purpose of this study is to evaluate the effects of spironolactone and furosemide on insulin resistance in patients with chronic heart failure.
Diuretics is useful in CHF patients. On the other hand, they deteriorate glucose metabolism. Therefore, the purpose of this study is to evaluate the effects of spironolactone and furosemide on insulin resistance in patients with chronic heart failure.
Study Started
Jan 31
2004
Study Completion
Dec 31
2005
Last Update
Apr 22
2008
Estimate

Drug spironolactone + furosemide

spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16weeks

Criteria 

Inclusion Criteria:

chronic stable heart failure

Exclusion Criteria:

renal dysfunction or under treatment with antidiabetic agents
No Results Posted